A
Alcista
Alcista · 25%CTMX
$4.13
Precio del escenario
$2.440
+0.041 (+1.67%)Al cierre
Loading chart…
- Máximo
- 2.470
- Apertura
- 2.380
- Precio medio ponderado por volumen
- 2.43
- Volumen
- 2.44M
- Capitalización
- 98.18M
- Mínimo
- 2.370
- Importe
- 5.93M
- EV/EBITDA, TTM
- -1.21
CytomX Therapeutics, Inc. is a clinical-stage, oncology-focused biopharmaceutical company. The Company is focused on developing conditionally activated, masked biologics designed to be localized to the tumor microenvironment. The Company is developing a pipeline of localized biologics, through its PROBODY therapeutic platform. Its pipeline comprises therapeutic candidates across multiple treatment modalities, including ADCs, T-cell engagers, and immune modulators such as cytokines. Its clinical-stage pipeline includes CX-2051, CX-904 and CX-801. CX-2051 is a masked, conditionally activated ADC directed toward EpCAM, armed with a topoisomerase-1 inhibitor payload. CX-904 is a masked, conditionally activated T-cell-engaging bispecific antibody targeting the EGFR on tumor cells and the CD3 receptor on T cells. CX-801 is a masked interferon alpha-2b PROBODY cytokine with broad potential applicability in traditionally immuno-oncology-sensitive as well as insensitive (cold) tumors.
Análisis de IA of CytomX Therapeutics Inc (CTMX)
VenderCytomX Therapeutics Inc is not a good buy right now. The current price is $2.28, which is significantly below the average analyst price target of $11 to $14, indicating potential upside. However, the stock has seen a staggering 46.35% year-to-date decline and a 92.4% year-over-year revenue drop to $1.42 million, which raises serious concerns about its financial health. The RSI is at 33.876, indicating oversold conditions, but the overall negative sentiment from recent earnings misses and cash reserve declines suggests caution. The main risk is the company's substantial revenue decline and ongoing losses, as evidenced by a net income of -$20.67 million in Q2 2026, which could further impact investor confidence and stock performance.
Recomendaciones de analistas (7)
+268.85% de potencial alcista
Comprar
6 Comprar
1 Mantener
0 Vender
Actual: 2.44
Mínimo
6.00
Promedio
9.00
Máximo
10.00
JPMorgan
Sobreponderar
$11
2026-08-13
JPMorgan
2026-08-13
Precio objetivo
$11
Sobreponderar
Guggenheim
Comprar
$14
2026-08-10
Guggenheim
2026-08-10
Precio objetivo
$14
Comprar
Wolfe Research
Superar al mercado
$6
2026-05-19
Wolfe Research
2026-05-19
Precio objetivo
$6
Superar al mercado
H.C. Wainwright
Comprar
$11
2026-05-11
H.C. Wainwright
2026-05-11
Precio objetivo
$11
Comprar
Piper Sandler
Sobreponderar
$12
2026-03-23
Piper Sandler
2026-03-23
Precio objetivo
$12
Sobreponderar
Métricas de valoración
El PER previsto actual de CytomX Therapeutics Inc (CTMX) es 14.20, frente a su media de 5 años de 15.81.
Escenarios de precio de Alphio AI para CTMX
Los precios por escenario son la última banda de previsión mensual del año en curso. Las probabilidades son pesos fijos del modelo (25 / 50 / 25), no garantías.
Ballenas con CTMX en cartera
Cronología de eventos
Noticias
9.008-27NASDAQ.COMCytomX Receives FDA Fast Track Designation for Varseta-M
9.008-27NewsfilterCytomX Receives FDA Fast Track Designation for Varseta-M
9.508-06seekingalphaCytomX Reports Q2 Earnings Miss with Significant Revenue Decline
8.507-06PRnewswireGT Biopharma Integrates AI to Accelerate Drug Development
5.007-01NASDAQ.COMRigel Pharmaceuticals Appoints New Chief Medical Officer
Preguntas frecuentes sobre CTMX, respondidas por Alphio AI
CytomX Therapeutics, Inc. is a clinical-stage, oncology-focused biopharmaceutical company. The Company is focused on developing conditionally activated, masked biologics designed to be localized to the tumor microenvironment. The Company is developing a pipeline of localized biologics, through its PROBODY therapeutic platform. Its pipeline comprises therapeutic candidates across multiple treatment modalities, including ADCs, T-cell engagers, and immune modulators such as cytokines. Its clinical-stage pipeline includes CX-2051, CX-904 and CX-801. CX-2051 is a masked, conditionally activated ADC directed toward EpCAM, armed with a topoisomerase-1 inhibitor payload. CX-904 is a masked, conditionally activated T-cell-engaging bispecific antibody targeting the EGFR on tumor cells and the CD3 receptor on T cells. CX-801 is a masked interferon alpha-2b PROBODY cytokine with broad potential applicability in traditionally immuno-oncology-sensitive as well as insensitive (cold) tumors. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).
CytomX Therapeutics Inc is not a good buy right now. The current price is $2.28, which is significantly below the average analyst price target of $11 to $14, indicating potential upside. However, the stock has seen a staggering 46.35% year-to-date decline and a 92.4% year-over-year revenue drop to $1.42 million, which raises serious concerns about its financial health. The RSI is at 33.876, indicating oversold conditions, but the overall negative sentiment from recent earnings misses and cash reserve declines suggests caution. The main risk is the company's substantial revenue decline and ongoing losses, as evidenced by a net income of -$20.67 million in Q2 2026, which could further impact investor confidence and stock performance.
7 analysts cover CTMX: 6 rate it Buy, 1 Hold and 0 Sell. The average price target is 9.00.
Comunidad
Más ↗Aún no hay publicaciones
Regístrate o inicia sesión para participarEsta página es solo para investigación y no constituye asesoramiento de inversión. Los modelos pueden equivocarse. El rendimiento pasado no garantiza resultados futuros.